The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.
The firms will develop a workflow for single cell genomic analysis using a modified version of Bio-Rad's droplet generator instrument.
The firms will develop a cost-effective, scalable solution that incorporates Bio-Rad's droplet partitioning technology with Illumina's NGS and BaseSpace data analysis.
Bio-Rad brought a claim before the American Arbitration Association in 2014, alleging that three 10X Genomics founders breached certain contractual obligations.
The UCSF-based Blood Systems Research Institute will conduct research using RainDance's digital PCR platforms as part of a new $20 million amfAR Institute for HIV Cure Research.
The ratings company cited Bio-Rad's historically low leverage and low debt load, which provides a cushion against the costs associated with internal projects.
The work identified specific groups of somatic mutations that might be ideal to hunt for in ctDNA to monitor tumor burden, guide treatment, or follow therapeutic response.
Sales were down in both the Life Sciences and Clinical Diagnostics segments, but the firm reported an increase in net income compared to the year-ago period.
Posters described Droplet Digital PCR for oncology, somatic mosaicism detection, and gene editing methods development.
Spokespersons from Bio-Rad noted that there appears to be an increasing number of researchers using ddPCR for methylation analyses.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.